共 41 条
[1]
Dolan P(2001)Utilitarianism and the measurement and aggregation of quality-adjusted life years Health Care Anal. 9 65-76
[2]
McCabe C(2008)The NICE cost-effectiveness threshold: what it is and what that means Pharmacoeconomics. 26 733-744
[3]
Claxton K(2014)Are the UK systems of innovation and evaluation of medical devices compatible? The role of NICE’s medical technologies evaluation programme (MTEP) Appl Health Econ Health Policy. 12 347-357
[4]
Culyer AJ(2014)Health technology assessments in England: an analysis of the NICE medical technologies evaluation programme Eur J Health Econ. 15 449-452
[5]
Chapman A(2009)Economic evaluation for devices and drugs: same or different? Value Health. 12 402-406
[6]
Taylor C(2013)The economic evaluation of medical devices: challenges ahead Appl Health Econ Health Policy. 11 15-26
[7]
Girling A(2009)Assessing the clinical and cost-effectiveness of medical devices and drugs: same or different? Value Health. 12 402-404
[8]
Green W(2007)Assessing the economic challenges posed by orphan drugs Int J Technol Assess. 23 36-42
[9]
Hutton J(2005)Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM. 98 829-836
[10]
Drummond M(2010)Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67 BMJ. 341 c4715-964